NSABP C-14/Exact Sciences 16-002: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.

Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...

Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.

The Patient Voice: MRD as a Tool of Hope and Anxiety Anne-Pierre Pickaert, a survivor of ALL and patient advocate, described MRD in profoundly personal terms. For many patients, MRD is both a ...

AUSTIN, Texas, July 07, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free ...

This approval underscores the assay’s robust analytical performance and clinical utility in the detection of MRD in patients with FLT3 ITD-mutated AML.

“These results reinforce the data previously presented at ASCO GI, where our tissue-free Latitude MRD assay demonstrated high overall concordance to Signatera™ as well as strong standalone ...

Among the 224 MRD-negative patients, 22 in each arm underwent allogeneic transplant. About 60% received all four cycles of blinatumomab, while 80% received two or more cycles.